Leukemia Research
Volume 32, Issue 2 , Pages 243-250 , February 2008

Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas

  • Semra Paydas

      Affiliations

    • Department of Oncology, Cukurova University Faculty of Medicine, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90 322 3386060; fax: +90 322 3386153.
    • ,
  • Melek Ergin

      Affiliations

    • Department of Pathology, Cukurova University Faculty of Medicine, Turkey
    • ,
  • Seyda Erdogan

      Affiliations

    • Department of Pathology, Cukurova University Faculty of Medicine, Turkey
    • ,
  • Gulsah Seydaoglu

      Affiliations

    • Department of Biostatistics, Cukurova University Faculty of Medicine, Turkey
    • ,
  • Sinan Yavuz

      Affiliations

    • Department of Oncology, Cukurova University Faculty of Medicine, Turkey
    • ,
  • Umut Disel

      Affiliations

    • Department of Oncology, Cukurova University Faculty of Medicine, Turkey

Received 21 January 2007 ,Revised 21 January 2007 ,Accepted 26 June 2007.

References 

  1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921
  2. Tamm I, Schriever F, Dörken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol. 2001;2:33–42
  3. Son BH, Choi JS, Lee JH. Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast. Pathology. 2005;37(2):131–136
  4. Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dörken B, Tamm I. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer. 2006;119:1291–1297
  5. Nakagawa Y, Hasegawa M, Kurata M, Yamamoto K, Abe S, Inoue M, et al. Expression of IAP-family proteins in adult acute mixed lineage leukemia. Am J Hematol. 2005;78:173–180
  6. Watanki-Miyauchi R, Kojima Y, Tsurami H, Hara T, Goto N, Kasahara S, et al. Expression of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int. 2005;55:324–330
  7. Tracey L, Perez-Rosado A, Artiga MJ, Camacho F, Rodriguez A, Martinez N, et al. Expression of the NF-k B targets BCL2 and BIRC5/survivin characterizes small B cell and aggressive B-cell lymphomas, respectively. J Pathol. 2005;206:123–134
  8. Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T. Regulation of survivin expression through BCR-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006;107:1555–1563
  9. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22:1682–1688
  10. Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N, et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol. 2004;164:501–510
  11. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–1925
  12. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54
  13. Kamihira S, Yamada Y, Hirakata Y, Tomanaga M, Sugahara K, Hayashi T, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukemia: survivin is an important determinant for prognosis. Br J Haematol. 2001;114:63–69
  14. Clezardin P, Lawler J, Amiral J, Quentin G, Delmas P. Identification of cell adhesive sites in the N-terminal domain of thrombospondin-1. Biochem J. 1997;321:819–827
  15. Lawler J, Ferro P, Duquette M. Expression and mutagenesis of thrombospondin. Biochemistry. 1992;31:1173–1180
  16. Merle B, Malaval L, Lawler J, Delmas P, Clezardin P. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Biochem. 1997;67:75–83
  17. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, et al. Inducer stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med. 2002;5:349–357
  18. Armstrong LC, Bornstein P. Thrombospondin-1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 2006;22:63–71
  19. Iuela-Aispe ML, Luque A, Lee N. Thrombospondin modulates and angiogenesis. Int J Biochem Cell Biol. 2004;35:1070–1076
  20. Lawler J, Detmer M. Tumor progression: the effects of thrombospondin-1 and 2. Int J Biochem Cell Biol. 2004;36:1036–1045
  21. Lawler J, Detmar M. Tmor progression: the effects of thrombospondin-1 and 2. Int J Biochem Cell Biol. 2004;36:1038–1045
  22. Desoize B. Stromal reaction and tumor growth. Crit Rev Oncol Hematol. 2004;49:173–176
  23. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int J Cancer. 2005;114:509–512
  24. Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JST, et al. Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Cancer. 2006;94:108–114
  25. Sarela AI, Macadam RC, Farnery SM, Markham AF, Guilou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000;46:645–650
  26. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2004;10:3737–3744
  27. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000;111:196–203
  28. Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk Lymphoma. 2002;43:2249–2255
  29. Kamihira S, Yamada Y, Hirakata Y, Tomonaga M, Sugahara K, Hayashi T, et al. Aberrant expression of cascade regulatory genes in adult T-cell leukemia: survivin is an important determinant for prognosis. Br J Haematol. 2001;114:63–69
  30. Che XF, Zheng CL, Owatari S, Mutch M, Gotando T, Jeung HC, et al. Overexpression of survivin in primary ATL cells and odium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. Blood. 2006;107:4880–4887
  31. Sugahara K, Uemura A, Harasawa H, Nagai H, Hirakata Y, Tomonaga M, et al. Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int J Hematol. 2004;80:52–58
  32. Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res. 2004;28:487–494
  33. Conte E, Stagno F, Guglielmo P, Scuto A, Consoli C, Messina A. Survivin expression in chronic myeloid leukemia. Cancer Lett. 2005;225:105–110
  34. Invernizzi R, Travaglino E, Benatti C, Malcovati L, Porta MD, Cazzola M, et al. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol. 2006;76:494–501
  35. Hui D, Satkunam N, Al Kaptan M, Reiman T, Lai R. Pathway-specific apoptotic gene expression profiling in chronic lymphocytic leukemia and follicular lymphoma. Mod Pathol. 2006;19:1192–1202
  36. Schlette EJ, Mederios LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large cell lymphoma. J Clin Oncol. 2004;22:1682–1688
  37. Xiang XJ, He YJ. Clinical significance of survivin and caspase-3 expression in diffuse large B-cell lymphoma. Zhonghua Zhong Liu Za Zhi. 2006;28:298–301
  38. Li JF, Li GD, Liu WP, Wang Y, Cheng JR, Chen Y, et al. Expression of anaplastic lymphoma kinase and survivin proteins in anaplastic large cell lymphoma and its significance. Zhonghua Bing Li Xue Za Zhi. 2006;35:213–217
  39. Xiang XJ, He YJ, Li YH, Huang H, Xu F. Clinical significance of survivin expression in peripheral T-cell lymphoma. Ai Zheng. 2006;25:758–761
  40. Zuo XL, Zhou X, Meng J, Zhang KJ, Liu XH, Yang HQ. A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin's lymphoma. Zhonghua Nei Ke Za Zhi. 2006;45:133–135
  41. Martinez A, Bellesilo B, Bosch F, Ferrer A, Marce S, Villamor N, et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol. 2004;164:501–510
  42. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–11182
  43. Siegel S, Wagner A, Schmitz N, Zeis M. Induction of antitumor immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol. 2003;122:911–914
  44. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol. 2003;170:5391–5397
  45. Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Welik LE, et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia. 2004;18:616–623
  46. Sid B, Sartelet H, Bellon G, Btaouri HE, Rath G, Delorme N, et al. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol. 2004;49:245–258
  47. Adams JC. Thrombospondins: multifunctional regulators of cell interactions. Ann Rev Cell Dev Biol. 2001;17:25–51
  48. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. PNAS. 2003;100:12917–12922
  49. Bellon G, Martiny L, Robinet A. Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol. 2004;49:203–220
  50. Gietema JA, Hoekstra R, de Vos FYFL, Uges DRA, der Gaast A, Greon HJM, et al. A phase I study assessing the safety of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol. 2006;17:1320–1327
  51. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor.
  52. Scarpino S, Di Napoli A, Taraboletti G, Cancrini A, Ruco LP. Hepatocyte growth factor (HGF) downregulates thrombospondin-1 (TSP-1) expression in thyroid papillary carcinoma cells. J Pathol. 2005;205:50–56
  53. Yee KO, Streit M, Hawighorst T, Detmer M, Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-β. Am J Pathol. 2004;165:541–552
  54. Albo D, Tuszynski GP. Thrombospondin 1 up regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells. J Surg Res. 2004;120:21–26
  55. Linderholm B, Karlsson E, Klaar S, Lindahl T, Borg AL, Elmberger G, et al. Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers. Eur J Cancer. 2004;40:2417–2423

☆ This study has been presented as poster in ESMO congress, 2006.

PII: S0145-2126(07)00260-3

doi: 10.1016/j.leukres.2007.06.024

Leukemia Research
Volume 32, Issue 2 , Pages 243-250 , February 2008

Article Tools

* Image Usage & Resolution